Trials / Completed
CompletedNCT00414947
Bioequivalence of Vildagliptin Tablet Manufactured in China Compared to Imported Vildagliptin Tablet in Chinese Healthy Volunteers
A Single Center, Randomized, Open-Label, Crossover, Single Oral Dose Study to Assess the Bioequivalence of LAF237 Tablet Manufactured by Beijing Novartis Pharma Ltd. to Imported LAF237 Tablet in Chinese Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (planned)
- Sponsor
- Novartis · Industry
- Sex
- Male
- Age
- 18 Years – 40 Years
- Healthy volunteers
- Accepted
Summary
This study will evaluate the bioequivalence as well as rate and extent of absorption of vildagliptin tablet manufactured by Beijing Novartis Pharma Ltd. compared to the imported vildagliptin tablet in Chinese healthy volunteers. This trial is not recruiting patients in the United States,
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Vildagliptin (LAF237) |
Timeline
- Start date
- 2006-12-01
- First posted
- 2006-12-22
- Last updated
- 2007-06-22
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT00414947. Inclusion in this directory is not an endorsement.